safety concerns

United Airlines CEO Scott Kirby raised safety concerns about eVTOL operations at crowded airports, threatening Archer Aviation's deal while boosting Joby's service-based model.

Class action lawsuit filed against $SLNO alleging failure to disclose fluid retention safety concerns in DCCR drug trials, harming investors who bought shares March-November 2025.

Investors in $SLNO have until May 5, 2026 to join securities lawsuit alleging undisclosed safety issues with DCCR drug candidate.

Soleno Therapeutics faces class action lawsuit over allegedly undisclosed fluid retention safety issues with DCCR drug candidate during March-November 2025 period.

Soleno Therapeutics faces class action lawsuit over safety concerns and inflated metrics for flagship drug VYKAT™ XR. Stock plunged 27% following August short report and November earnings disappointment.

Soleno Therapeutics faces securities litigation alleging undisclosed DCCR safety risks during March-November 2025. Lead plaintiff deadline: May 5, 2026.

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

Rosen Law Firm alerts $SLNO investors of May 5, 2026 deadline in securities class action alleging false statements about DCCR drug candidate safety risks.

Class action filed against $SLNO for allegedly failing to disclose safety concerns about DCCR drug. Stock fell sharply after August 2025 short report and September patient death disclosure.

Soleno Therapeutics faces class action lawsuit alleging failure to disclose material DCCR drug safety concerns, including excess fluid retention in clinical trials that reduced commercial viability.

Baidu Apollo Go robotaxis experienced system outages in Wuhan, stranding passengers. Despite safety concerns, the company reported surpassing 20 million lifetime rides in Q4.

Class action lawsuit filed against $SLNO alleging fraud over PWS drug DCCR. Safety concerns, patient death, and commercial disruption emerged in 2025.

Securities lawsuit alleges $SLNO concealed safety concerns about DCCR, its only commercial product for Prader-Willi syndrome treatment, ahead of May 5, 2026 lead plaintiff deadline.

Soleno Therapeutics faces securities lawsuit alleging undisclosed safety risks in its sole commercial product DCCR. Investors have until May 5, 2026 to seek lead plaintiff status.

Class action lawsuit filed against $SLNO alleging failure to disclose safety concerns about DCCR drug candidate, including fluid retention issues in clinical trials.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

Soleno Therapeutics faces class action lawsuit over alleged failure to disclose safety issues with drug DCCR, following 12-27% stock declines from August-September 2025 revelations.

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.